Zhitong Finance App News, Nuochengjianhua (688428.SH) announced that the new-generation TRK inhibitor zolecutinib tablets (trade name: inoxin®) independently developed by the company were included in the new national medical insurance catalogue to treat adults carrying the NTRK fusion gene and patients with solid tumors in adolescents aged 12 and over. The new version of the National Health Insurance Catalogue will be officially implemented from January 1, 2027. The agreement is valid from January 1, 2027 to December 31, 2028.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Nuochengjianhua (688428.SH) announced that the new-generation TRK inhibitor zolecutinib tablets (trade name: inoxin®) independently developed by the company were included in the new national medical insurance catalogue to treat adults carrying the NTRK fusion gene and patients with solid tumors in adolescents aged 12 and over. The new version of the National Health Insurance Catalogue will be officially implemented from January 1, 2027. The agreement is valid from January 1, 2027 to December 31, 2028.